Results 51 to 60 of about 373,608 (350)

Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis

Frontiers in Oncology
IntroductionThis meta-analysis was performed to evaluate the efficacy and safety of angiogenesis inhibitors (Ais) combined with poly ADP ribose polymerase inhibitors (PARPi) in the maintenance treatment of advanced ovarian cancer (OC).Materials and ...
Renming Huang, Feng Ji, Leyi Huang, Yueying Qin, Zhiyu Liang, Miaoyan Huang, Chunyan Li, Jian Ban   +7 more
doaj   +1 more source

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source

Electrochemical sensing of angiogenin induced endothelial nitric oxide synthase activity [PDF]

, 2009
This paper was presented at the 2nd Micro and Nano Flows Conference (MNF2009), which was held at Brunel University, West London, UK. The conference was organised by Brunel University and supported by the Institution of Mechanical Engineers, IPEM, the ...
2nd Micro and Nano Flows Conference (MNF2009), Chang, SI, Chung, HM, Kang, DK, O'Hare, D, Trouillon, R   +5 more
core  

Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis [PDF]

, 2014
We have shown in vitro that thyroid hormones (THs) regulate the balance between proliferation and apoptosis of T lymphoma cells. The effects of THs on tumor development have been studied, but the results are still controversial.
Barreiro Arcos, María Laura, Cayrol, Maria Florencia, Colombo, L., Cremaschi, Graciela Alicia, Díaz Flaqué, María Celeste, Klecha, Alicia Juana, Martinel Lamas, Diego José, Medina, Vanina Araceli, Paulazo, Maria Alejandra, Sterle, Helena Andrea, Valli, Eduardo   +10 more
core   +1 more source

Controlling escape from angiogenesis inhibitors [PDF]

Nature Reviews Cancer, 2012
Selective inhibition of vascular endothelial growth factor (VEGF) increases the efficacy of chemotherapy and has beneficial effects on multiple advanced cancers, but response is often limited and the disease eventually progresses. Changes in the tumour microenvironment--hypoxia among them--that result from vascular pruning, suppressed angiogenesis and ...
Sennino, Barbara, McDonald, Donald M
openaire   +4 more sources

Multiple ETS family transcription factors bind mutant p53 via distinct interaction regions

FEBS Letters, EarlyView.
Mutant p53 gain‐of‐function is thought to be mediated by interaction with other transcription factors. We identify multiple ETS transcription factors that can bind mutant p53 and found that this interaction can be promoted by a PXXPP motif. ETS proteins that strongly bound mutant p53 were upregulated in ovarian cancer compared to ETS proteins that ...
Stephanie A. Metcalf, Nicholas F. Downing, Kaitlyn M. Mills, Samuel C. Metcalfe, Alexander E. Kritzer, Lindsey D. Mayo, Peter C. Hollenhorst   +6 more
wiley   +1 more source

Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer

Cellular Physiology and Biochemistry, 2017
Background/Aims: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human malignancies, and there is no efficient method to slow its process. Apatinib, a novel tyrosine kinase inhibitor (TKI), has been confirmed for its efficacy and safety in ...
Zhijian Jin, Xi Cheng, Haoran Feng, Jie Kuang, Weiping Yang, Chenghong Peng, Baiyong Shen, Weihua Qiu   +7 more
doaj   +1 more source

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022

Frontiers in Immunology, 2023
BackgroundImmune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) have become increasingly available for multiple types of cancers, although the cardiovascular safety profiles of this combination therapy in real-world settings ...
Yanfeng Wang, Chanjuan Cui, Lei Deng, Lin Wang, Xiayang Ren   +4 more
doaj   +1 more source

Angiogenesis and angiogenesis inhibitors in paediatric diseases

European Journal of Pediatrics, 1992
Angiogenesis, the generation of new capillaries from existing blood vessels, is rarely observed in the healthy organism, but can present during various paediatric diseases. In this review, we describe recent progress in the understanding of pathological angiogenesis and approaches for an improved therapy of angiogenic childhood diseases.
Schweigerer, L., Fotsis, T.
openaire   +3 more sources

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source